Parent Project Muscular Dystrophy Celebrates Successful 2nd Annual August Blues Fishing Tournament
Second annual
This year's tournament saw more than 230 participants, including men, women, and juniors of all ages and from across the
PPMD's Founding President and CEO,
PPMD extends its heartfelt thanks to the Chotkowski family, tournament sponsors, and participants who made the 2024 August Blues Fishing Tournament an outstanding success. The funds raised will play a pivotal role in advancing our efforts to improve the quality of life for all individuals living with Duchenne and their families.
ABOUT PARENT PROJECT MUSCULAR DYSTROPHY
Duchenne is a genetic disorder that slowly robs people of their muscle strength. Parent Project Muscular Dystrophy (PPMD) fights every single battle necessary to end Duchenne.
We demand optimal care standards and ensure every family has access to expert healthcare providers, cutting edge treatments, and a community of support. We invest deeply in treatments for this generation of Duchenne patients and in research that will benefit future generations. Our advocacy efforts have secured hundreds of millions of dollars in funding and won eight FDA approvals.
Everything we do—and everything we have done since our founding in 1994—helps those with Duchenne live longer, stronger lives. We will not rest until we end Duchenne for every single person affected by the disease. Join our fight against Duchenne at EndDuchenne.org. Follow PPMD on Facebook, Twitter, Instagram, and YouTube.
View original content to download multimedia:https://www.prnewswire.com/news-releases/parent-project-muscular-dystrophy-celebrates-successful-2nd-annual-august-blues-fishing-tournament-302238994.html
SOURCE Parent Project Muscular Dystrophy (PPMD)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dutch Bros® and the Dutch Bros Foundation® Rally Customers for 20th Annual Buck for Kids Day to Support Local Youth
- AbelZeta Receives FDA IND Clearance for Phase 1b/2 Clinical Trial of C-CAR168 in Progressive Multiple Sclerosis
- TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Bloo
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share